Fintel reports that on December 3, 2025, BTIG reiterated coverage of NRx Pharmaceuticals (NasdaqCM:NRXP) with a Buy recommendation.
Analyst Price Forecast Suggests 1,540.09% Upside
As of November 17, 2025, the average one-year price target for NRx Pharmaceuticals is $37.23/share. The forecasts range from a low of $25.25 to a high of $49.35. The average price target represents an increase of 1,540.09% from its latest reported closing price of $2.27 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for NRx Pharmaceuticals is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -0.36.
What is the Fund Sentiment?
There are 36 funds or institutions reporting positions in NRx Pharmaceuticals. This is an increase of 1 owner(s) or 2.86% in the last quarter. Average portfolio weight of all funds dedicated to NRXP is 0.25%, an increase of 6.09%. Total shares owned by institutions increased in the last three months by 29.22% to 4,256K shares. 
The put/call ratio of NRXP is 0.01, indicating a bullish outlook.
What are Other Shareholders Doing?
Anson Funds Management holds 2,025K shares representing 7.21% ownership of the company. In its prior filing, the firm reported owning 1,605K shares , representing an increase of 20.75%. The firm decreased its portfolio allocation in NRXP by 19.61% over the last quarter.
AdvisorShares Investments holds 342K shares representing 1.22% ownership of the company. In its prior filing, the firm reported owning 264K shares , representing an increase of 22.90%. The firm increased its portfolio allocation in NRXP by 18.94% over the last quarter.
PSIL - AdvisorShares Psychedelics ETF holds 264K shares representing 0.94% ownership of the company. In its prior filing, the firm reported owning 287K shares , representing a decrease of 8.72%. The firm increased its portfolio allocation in NRXP by 22.71% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 252K shares representing 0.90% ownership of the company. No change in the last quarter.
Marshall Wace, Llp holds 189K shares representing 0.67% ownership of the company. In its prior filing, the firm reported owning 33K shares , representing an increase of 82.35%. The firm increased its portfolio allocation in NRXP by 152.77% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
